CSU secures $3.1 million from NIH to advance SolaVAX coronavirus vaccine research
FORT COLLINS -- A team of scientists at Colorado State University was awarded a base contract worth $3.1 million from the National Institutes of Health to continue development... Read More
Tuesday September 22, 2020
INterview with Dennis Pierro, BioMARC director
Dennis Pierro has been director of BioMARC , a biopharmaceuticalmanufacturing organization at Colorado State University in Fort Collins, since 2012.BioMARC produces therapeutics, diagnostics... Read More
Friday March 31, 2017
CSU's BioMARC secures $3M DoD grant to create vaccine to protect soldiers
FORT COLLINS -- Colorado State Universitys vaccine manufacturing facility, BioMARC, is developing a drug to protect U.S. soldiers from a mosquito-borne pathogen that can cause severe illness and... Read More
Tuesday February 28, 2017
CSU’s BioMARC awarded $4.6M contract to develop new encephalitis vaccines
FORT COLLINS -- Colorado State University today announced its Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC) has been awarded a 10-month, $4.6 million contract from the... Read More
Wednesday January 13, 2016
CSU's BioMARC awarded $2M to help develop Ebola, filovirus vaccine
FORT COLLINS - Colorado State University's Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC) has been awarded $2 million by the U.S. Department of Defense to aid in the... Read More
Monday October 27, 2014